[{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Eli Lilly ","highestDevelopmentStatusID":"1","companyTruncated":"AbCellera \/ Eli Lilly "},{"orgOrder":0,"company":"AbCellera","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"COVID-19 antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0.17999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"AbCellera \/ Government of Canada","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Government of Canada"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"AbCellera","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0.11,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"AbCellera \/ OrbiMed","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ OrbiMed"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ AbCellera","highestDevelopmentStatusID":"10","companyTruncated":"AbCellera \/ AbCellera"},{"orgOrder":0,"company":"AbCellera","sponsor":"Invetx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Monoclonal Antibodies","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Invetx"},{"orgOrder":0,"company":"AbCellera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbCellera \/ Not Applicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"IgM antibodies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ IGM Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ IGM Biosciences"},{"orgOrder":0,"company":"AbCellera","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Kodiak Sciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Kodiak Sciences"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ AbCellera","highestDevelopmentStatusID":"12","companyTruncated":"AbCellera \/ AbCellera"},{"orgOrder":0,"company":"AbCellera","sponsor":"Trianni","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Human antibodies","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"AbCellera \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ AbCellera"},{"orgOrder":0,"company":"AbCellera","sponsor":"Invetx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Monoclonal antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Invetx"},{"orgOrder":0,"company":"AbCellera","sponsor":"BMO Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Bamlanivimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AbCellera","amount2":0.35999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"AbCellera \/ BMO Capital Markets","highestDevelopmentStatusID":"12","companyTruncated":"AbCellera \/ BMO Capital Markets"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ AbCellera","highestDevelopmentStatusID":"12","companyTruncated":"AbCellera \/ AbCellera"},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ AbCellera Biologics","highestDevelopmentStatusID":"9","companyTruncated":"AbCellera \/ AbCellera Biologics"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"AbCellera","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Humanized antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Gilead Sciences"},{"orgOrder":0,"company":"AbCellera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbCellera \/ Not Applicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"LY3853113","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Eli lilly","highestDevelopmentStatusID":"8","companyTruncated":"AbCellera \/ Eli lilly"},{"orgOrder":0,"company":"AbCellera","sponsor":"Tachyon Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"TACH204","moa":"LEFTY1","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Tachyon","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Tachyon"},{"orgOrder":0,"company":"AbCellera","sponsor":"TetraGenetics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Antibodies","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera \/ AbCellera"},{"orgOrder":0,"company":"AbCellera","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Bispecific Antibodies","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Everest Medicines","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Everest Medicines"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AbCellera \/ AbCellera Biologics","highestDevelopmentStatusID":"12","companyTruncated":"AbCellera \/ AbCellera Biologics"},{"orgOrder":0,"company":"AbCellera","sponsor":"Vaccine Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Vaccine Research Center","highestDevelopmentStatusID":"8","companyTruncated":"AbCellera \/ Vaccine Research Center"},{"orgOrder":0,"company":"AbCellera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CD3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Not Applicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Empirico","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Antibody-based Therapy","moa":"GPCR","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ AbCellera"},{"orgOrder":0,"company":"AbCellera","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Versant Ventures"},{"orgOrder":0,"company":"AbCellera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CD3","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Not Applicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"AbCellera","sponsor":"Rallybio","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Rallybio","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Rallybio"},{"orgOrder":0,"company":"AbCellera","sponsor":"RQ Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ RQ Bio","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera \/ RQ Bio"},{"orgOrder":0,"company":"AbCellera","sponsor":"Confo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"BELGIUM","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"GPCR Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera \/ AbCellera"},{"orgOrder":0,"company":"AbCellera","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Incyte Corporation"},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Large molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"AbCellera","sponsor":"Prelude Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera \/ AbCellera"},{"orgOrder":0,"company":"AbCellera","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Biogen"},{"orgOrder":0,"company":"AbCellera","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"ABCL575","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Viking Global Investors","highestDevelopmentStatusID":"5","companyTruncated":"AbCellera \/ Viking Global Investors"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Large molecule","year":"2024","type":"Expanded Collaboration","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"AbCellera \/ Eli Lilly"}]
Find Clinical Drug Pipeline Developments & Deals by AbCellera
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
